Gene-centric functional dissection of human genetic variation uncovers regulators of hematopoiesis
- Harvard Medical School, United States
- Broad Institute of MIT and Harvard, United States
- Ruprecht-Karls-University Heidelberg, Germany
- University of Oxford, United Kingdom
- Harvard Stem Cell Institute, United States
- Harvard University, United States
- Cleveland Clinic, United States
- Brigham and Women’s Hospital, United States
- Dana-Farber Cancer Institute, United States
- Howard Hughes Medical Institute, United States
Figures
Figure 1 with 3 supplements
Design and Execution of an shRNA Screen Using Blood Cell Trait GWAS Hits to Identify Genetic Actors in Erythropoiesis.
(A) Overview of shRNA library design.75 loci associated with red blood cell traits (van der Harst et al., 2012) were used as the basis to calculate 75 genomic windows of LD 0.8 or greater from the …
-
Figure 1—source data 1
Table containing annotations and information for the 75 SNPs used to seed the shRNA library.
- https://doi.org/10.7554/eLife.44080.006
-
Figure 1—source data 2
Table containing annotations and information for all hairpins, as well as shRNA counts for each time point and replicate.
- https://doi.org/10.7554/eLife.44080.007
Figure 1—figure supplement 1
Characteristics of GWAS Loci and Gene Selection for Pooled Screen.
(A) Counts of loci from among the original 75 annotated with linkage to each of the six RBC traits, hemoglobin (Hb), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration …
Figure 1—figure supplement 2
Feasibility of Loss of Function Approaches to Perform Pooled Screens in Primary Hematopoietic Stem and Progenitor Cells (HSPCs).
(A) Schematic of the loss of function lentiviral constructs tested for pooled screens in primary CD34+ cells. (B) FACS plots showing the proportion of infected GFP+ cells 4 days after transduction …
Figure 1—figure supplement 3
Pooled shRNA screen in primary HSPCs undergoing erythroid differentiation.
(A) Histogram showing distribution of number of independent hairpins included in the library to target each of the candidate’s genes. (B) Representative FACS plots of erythroid cell surface markers …
Figure 2 with 2 supplements
Summary Characterization of shRNA Screen Outcomes.
(A) Kernel density plot showing library representation as log2 shRNA CPM across all hairpins. (B) shRNA abundance log2 fold changes from day 4 to day 16. Represented values are the mean of hairpin …
Figure 2—figure supplement 1
shRNA abundance log2 fold changes from day four to each of the other time points.
Represented values are the mean of hairpin abundance log2 fold changes across hairpins for each gene and two standard deviations.
Figure 2—figure supplement 2
Scatter plots showing agreement of replicate observations across independent CD34+ donor populations.
https://doi.org/10.7554/eLife.44080.010
Figure 3 with 3 supplements
Statistical Modeling of Gene Effect Accounting for Off-target shRNA Confounders.
(A) Bar graph showing the 38 of 75 loci in the screen with at least one corresponding statistically significant (FDR < 0.1, β >0.1) gene effect causing either a positive or negative log2 fold change …
-
Figure 3—source data 1
Table containing the R model output for each gene.
- https://doi.org/10.7554/eLife.44080.015
Figure 3—figure supplement 1
Additional Characterization of Modeling Outcomes.
(A) Histogram showing the number of gene hits identified at each of the 40 loci with at least one significant gene effect detected. Statistical model output for each gene in screen available in Figur…
Figure 3—figure supplement 2
K562 Essentiality Scores Comparing Hit Genes vs.Genes Implicated by Other Traits.
(A) Permuted enrichment of essentiality among the set of hit genes vs. randomly chosen sets of genes from the human genome. (B) Permuted enrichment of essentiality among the set of hit genes vs. …
Figure 3—figure supplement 3
Heat map depicting strength of expression (as z scores within each gene) for each of the 77 identified hit genes throughout the specific stages of fetal erythropoiesis.
Purple boxes highlight the cell types that were enriched for expression of hit genes.
Figure 4
Analysis of Interactions Among Members of the Hit Set Identifies Signaling/Transcription, Membrane, and mRNA Translation-Related Subnetworks Important to Erythropoiesis.
STRING interaction network analysis identifies signaling/transcription, membrane, and mRNA translation-related subnetworks important to erythropoiesis embedded in the genes identified in the screen …
Figure 5 with 1 supplement
Transferrin receptor two is a Negative Regulator of Human Erythropoiesis.
(A) Quantitative RT-PCR and (B) Western blot showing the expression of TFR2 in human CD34+ cells five days post-infection with the respective lentiviral shRNAs targeting TFR2 (TFR2 sh1 and sh2) and …
Figure 5—figure supplement 1
Additional Analysis Showing Transferrin Receptor two is a Negative Regulator of Human Erythropoiesis.
(A) Representative FACS plots of alternate erythroid cell surface markers CD49d (α4 integrin) and CD235a (Glycophorin A) expression at various time points during erythroid differentiation. (B) …
Figure 6 with 2 supplements
SF3A2 is a Key regulator of Human Erythropoiesis and Modulates Erythropoiesis Defects in a Murine Model of MDS.
(A) Quantitative RT-PCR and (B) Western blot showing the expression of SF3A2 in human CD34+ cells five days post-infection with the respective lentiviral shRNAs targeting SF3A2 (sh1-4) and a control …
-
Figure 6—source data 1
Table containing the DESeq2 output for differentially expressed genes in cells undergoing SF3A2 knockdown or control shRNA treatment.
- https://doi.org/10.7554/eLife.44080.022
-
Figure 6—source data 2
Table containing the DESeq2 output for differentially expressed genes in MDS patients with and without mutations in SF3B1.
- https://doi.org/10.7554/eLife.44080.023
-
Figure 6—source data 3
Tables containing the GO component (Table 1) and function (Table 2) enrichments calculated using GOrilla for cells undergoing SF3A2 knockdown or control shRNA treatment.
- https://doi.org/10.7554/eLife.44080.024
-
Figure 6—source data 4
Tables containing the GO component (Table 1) and function (Table 2) enrichments calculated using GOrilla for MDS patient samples with and without mutations in SF3B1.
- https://doi.org/10.7554/eLife.44080.025
-
Figure 6—source data 5
Tables containing the differential splicing analysis for cells undergoing SF3A2 knockdown or control shRNA treatment.
Categories of splice mutations presented in each table are alternative 3’ splice sites, alternative 5’ splice sites, mutually exclusive exons, retrained introns, and skipped exons, respectively.
- https://doi.org/10.7554/eLife.44080.026
-
Figure 6—source data 6
Tables containing the differential splicing analysis for MDS patient patient samples with and without mutations in SF3B1.
Categories of splice mutations presented in each table are alternative 3’ splice sites, alternative 5’ splice sites, mutually exclusive exons, retrained introns, and skipped exons, respectively.
- https://doi.org/10.7554/eLife.44080.027
Figure 6—figure supplement 1
Additional Analysis Showing SF3A2 is Required for Human Erythropoiesis.
(A) shRNAs targeting SF3A2 co-expressing a reporter GFP gene was infected into human CD34+ cells and cultured in erythroid conditions. GFP expression at various time points from three independent …
Figure 6—figure supplement 2
Additional Analysis of Erythropoiesis Defects Observed in Sf3b1K700E Murine Erythroid Cells upon SF3A2 knockdown.
(A) Knockdown efficiency of shRNAs targeting SF3A2 in murine erythroleukemia (MEL) cells by western blot. (B) Total cell numbers of GFP +shRNA expressing bone marrow cells from wildtype (WT) and Sf3b…
Tables
Key resources table
| Reagent type (species) or resource | Designation | Source or reference | Identifiers | Additional information |
|---|---|---|---|---|
| Biological sample (Homo sapiens) | CD34 + mobilized peripheral blood | Fred Hutchinson Cancer Research Center | ||
| Cell line (Homo sapiens) | UT-7/EPO | NA | RRID:CVCL_5202 | maintained in Sankaran laboratory |
| Cell line (Mus musculus) | MEL | NA | maintained in Sankaran laboratory | |
| Genetic reagent (Mus musculus) | Sf3b1K700E | Obeng et al., 2016 | Dr. Benjamin L. Ebert (Brigham Women's Hospital, Boston MA) | |
| Recombinant DNA reagent (lentiviral shRNA) | PLKO.1-Puro (plasmid) | Sigma-Aldrich | RRID :Addgene_10878 | Pol III based shRNA backbone |
| Recombinant DNA reagent (lentiviral shRNA) | PLKO-GFP (plasmid) | this paper | GFP version of pLKO.1-Puro | |
| Recombinant DNA reagent (lentiviral shRNA) | SFFV-Venus-mir30 shRNA (plasmid) | this paper | Pol II based shRNA backbone | |
| Antibody | mouse monoclonal anti-human CD235a-APC | Thermo Fisher Scientific | Cat#: 17-9987-42; RRID:AB_2043823 | FACS (5 ul per test) |
| Antibody | mouse monoclonal anti-human CD71-FITC | Thermo Fisher Scientific | Cat#: 11-0719-42; RRID:AB_1724093 | FACS (5 ul per test) |
| Antibody | mouse monoclonal anti-human CD71-PEcy7 | Thermo Fisher Scientific | Cat#: 25-0719-42; RRID:AB_2573366 | FACS (5 ul per test) |
| Antibody | mouse monoclonal ant-human CD49d-PE | Miltenyi Biotec | Cat#: 130-093-282; RRID:AB_1036224 | FACS (10 ul per test) |
| Antibody | mouse monoclonal anti-human CD41a-PE | Thermo Fisher Scientific | Cat#: 12-0419-42; RRID:AB_10870785 | FACS (5 ul per test) |
| Antibody | mouse monoclonal anti-human CD11b-PE | Thermo Fisher Scientific | Cat#: 12-0118-42; RRID:AB_2043799 | FACS (5 ul per test) |
| Antibody | Rat monoclonal anti-mouse Ter119-APC | Thermo Fisher Scientific | Cat#: 17-5921-82; RRID:AB_469473 | FACS (0.25 ug/test) |
| Antibody | Rat monoclonal anti-mouse CD71-PE | Thermo Fisher Scientific | Cat#: 12-0711-82; RRID:AB_465740 | FACS (0.5 ug/test) |
| Antibody | mouse monoclonal anti-phospho STAT5 Alexa Fluor-647 | BD Bioscience | Cat#: 612599; RRID:AB_399882 | FACS (1:20) |
| Antibody | mouse monoclonal anti-GAPDH | Santa Cruz Biotechnology | sc-32233; RRID:AB_627679 | Western (1:20,000) |
| Antibody | mouse monoclonal anti-TFR2 | Santa Cruz Biotechnology | sc-32271; RRID:AB_628395 | Western (1:200) |
| Antibody | mouse monoclonal anti-SF3A2 | Santa Cruz Biotechnology | sc-390444 | Western (1:1000) |
| Sequence-based reagent | shLUC | Sigma-Aldrich | TRCN0000072259 | 5’- CGCTGAGTACTTCGAAATGTC-3’ |
| Sequence-based reagent | TFR2 sh1 (human) | Sigma-Aldrich | TRCN0000063628 | 5’-GCCAGATCACTACGTTGTCAT-3’ |
| Sequence-based reagent | TFR2 sh2 (human) | Sigma-Aldrich | TRCN0000063632 | 5-CAACAACATCTTCGGCTGCAT-3’ |
| Sequence-based reagent | SF3A2 sh1 (human) | Sigma-Aldrich | TRCN0000000060 | 5’-CTACGAGACCATTGCCTTCAA-3’ |
| Sequence-based reagent | SF3A2 sh2 (human) | Sigma-Aldrich | TRCN0000000061 | 5’-CCTGGGCTCCTATGAATGCAA-3’ |
| Sequence-based reagent | SF3A2 sh3 (human) | Sigma-Aldrich | TRCN0000000062 | 5’-CAAAGTGACCAAGCAGAGAGA-3’ |
| Sequence-based reagent | SF3A2 sh4 (human) | Sigma-Aldrich | TRCN0000000063 | 5’-ACATCAACAAGGACCCGTACT-3’ |
| Commercial assay or kit | RNeasy Mini Kit | QIAGEN | Cat#: 74104 | |
| Commercial assay or kit | iScript cDNA synthesis Kit | Bio-Rad | Cat#: 1708891 | |
| Commercial assay or kit | iQ SYBR Green Supermix | Bio-Rad | Cat#: 170–8882 | |
| Commercial assay or kit | NucleoSpin Blood XL-Maxi kit | Clonetch | Cat#: 740950.1 | |
| Commercial assay or kit | Lineage Cell Depletion Kit (mouse) | Miltenyi | Cat#: 130-090-858 | |
| Commercial assay or kit | Nextera XT DNA Library Preparation Kit | Illumina | Cat#: FC-131–1096 | |
| Commercial assay or kit | NextSeq 500/550 High Output Kit v2.5 (75 Cycles) | Illumina | Cat#: 20024906 | |
| Commercial assay or kit | Bioanalyzer High Sensitivity DNA Analysis | Agilent | Cat#: 5067–4626 | |
| Commercial assay or kit | Agencourt AMPure XP | Beckman-Coulter | Cat#: A63881 | |
| Commercial assay or kit | TaKaRa Ex TaqDNA Polymerase | Takara | Cat#: RR001B | |
| Commercial assay or kit | Qubit dsDNA HS Assay Kit | Thermo Fisher | Cat#: Q32854 | |
| Chemical compound, drug | Human Holo-Transferrin | Sigma Aldrich | Cat#: T0665-1G | |
| Peptide, recombinant protein | Humulin R (insulin) | Lilly | NDC 0002-8215-01 | |
| Peptide, recombinant protein | Heparin | Hospira | NDC 00409-2720-01 | |
| Peptide, recombinant protein | Epogen (recombinant erythropoietin) | Amgen | NDC 55513-267-10 | |
| Peptide, recombinant protein | Recombinant human stem cell factor (SCF) | Peprotech | Cat#: 300–07 | |
| Peptide, recombinant protein | Recombinant human interleukin-3 (IL-3) | Peprotech | Cat#: 200–03 | |
| Peptide, recombinant protein | Recombinant mousestem cell factor (SCF) | R&D systems | Cat# 455-MC-010 | |
| Peptide, recombinant protein | recombinant mouse Insulin like Growth Factor 1 (IGF1) | R&D systems | Cat# 791 MG-050 | |
| Chemical compound, drug | Hoechst 33342 | Life Technologies | Cat#: H1399 | FACS (1:1000) |
| Chemical compound, drug | Fixation Buffer | BD Bioscience | Cat#: 554655 | |
| Chemical compound, drug | Perm Buffer III | BD Bioscience | Cat#: 558050 | |
| Chemical compound, drug | May-Grünwald Stain | Sigma-Aldrich | Cat#: MG500 | |
| Chemical compound, drug | Giemsa Stain | Sigma-Aldrich | Cat#: GS500 | |
| Software, algorithm | STAR | Dobin et al., 2013 | RRID:SCR_015899 | |
| Software, algorithm | MISO | Katz et al., 2010 | RRID:SCR_003124 | |
| Software, algorithm | R | The R Foundation | RRID:SCR_001905 | |
| Software, algorithm | Salmon | Patro et al., 2017 | RRID:SCR_017036 | |
| Software, algorithm | GOrilla | Eden et al., 2009 | RRID:SCR_006848 | |
| Software, algorithm | VEP | McLaren et al., 2016 | RRID:SCR_007931 | |
| Software, algorithm | FlowJo version 10 | FlowJo | RRID:SCR_008520 | |
| Software, algorithm | GraphPad Prism 7 | GraphPad Software Inc | RRID:SCR_002798 | |
| Software, algorithm | Python 2, 3 | Python Software Foundation | RRID:SCR_008394 | |
| Software, algorithm | PLINK | Chang et al., 2015 | RRID:SCR_001757 | |
| Software, algorithm | PoolQ | Broad Institute | https://portals.broadinstitute.org/gpp/public/software/poolq | |
Additional files
-
Transparent reporting form
- https://doi.org/10.7554/eLife.44080.028
